scholarly journals Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non‐small cell lung cancer

2019 ◽  
Vol 10 (3) ◽  
pp. 526-532 ◽  
Author(s):  
Yuki Katayama ◽  
Tadaaki Yamada ◽  
Keiko Tanimura ◽  
Akihiro Yoshimura ◽  
Takayuki Takeda ◽  
...  
2020 ◽  
Vol 21 (5) ◽  
pp. e405-e414
Author(s):  
Taichi Miyawaki ◽  
Hirotsugu Kenmotsu ◽  
Keita Mori ◽  
Eriko Miyawaki ◽  
Nobuaki Mamesaya ◽  
...  

2020 ◽  
Vol 2020 (4-5) ◽  
Author(s):  
Naoko Miura ◽  
Taichi Matsubara ◽  
Shinkichi Takamori ◽  
Naoki Haratake ◽  
Ryo Toyozawa ◽  
...  

Abstract The transformation of adenocarcinoma to small cell lung cancer has been reported as acquisition of resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors. We here report a patient who presented histologically confirmed transformation of adenocarcinoma to small cell lung cancer after treatment with immune checkpoint inhibitor. A 65-year-old man was treated with pembrolizumab as first-line therapy and achieved temporarily a stable disease with progression after six cycles of this agent. At that stage, a transbronchial biopsy showed small cell lung cancer, and he was found to have high serum concentrations of neuron-specific enolase despite concentrations of numerous tumor markers, including neuron-specific enolase, having been within normal limits at the time of presentation. The patient thereafter was treated as a small cell carcinoma patient using cisplatin plus irinotecan and amrubicin.


Sign in / Sign up

Export Citation Format

Share Document